GUBRA — Gubra A/S Share News
0.000.00%
Last trade - 00:00- DKK4.95bn
- DKK4.24bn
- DKK2.64bn
Brief: Gubra Targets Portfolio Of 8-10 Clinical-Stage Assets By 2030
Brief: Gubra Announces Achievement Of Milestone From AbbVie
Brief: Gubra H1 EBIT Loss DKK 122.9 Mln
Brief: Gubra Starts Phase 1/2A Clinical Trial Of GUB-UCN2 In Obesity
Brief: Gubra Q1 EBIT Amounts To DKK -41.3 Million
Brief: Partner Advances Gubra Originated Obesity Triple Agonist Peptide Into Phase 2
Brief: Gubra's Partner Abbvie Reports Positive Phase 1 Results For ABBV-295
Brief: Gubra 2025 Group Operating Profit At DKK 2.2 Billion
Brief: Gubra Submits Clinical Trial Application For GUB-UCN2 In Germany
Brief: Gubra Launches Gubra Ventures
Brief: Gubra: Amylyx Selects AMX0318 As Development Candidate
Brief: Gubra Expands Lab, Office Space By 70%
Brief: Gubra And Camurus Enter Into Collaboration And License Agreement
Brief: Gubra Partner Boehringer Ingelheim Advances Treatment Of Obesity Into Mid-Stage Development
Brief: Gubra Q3 Adjusted EBIT Turns To Loss At DKK 6.1 Mln YoY
Brief: Gubra Cuts FY 2025 CRO Revenue Outlook
Brief: Gubra H1 EBIT At DKK 2.3 Bln
Brief: Gubra Appoints Markus Rohrwild As CEO
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial